Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

98.50 -1.16 (-1.16%)
Official Closing Price Updated: 6:30 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,802,730
Open 99.93
Bid (Size) 98.52 (1)
Ask (Size) 99.65 (1)
Prev. Close 99.66
Today's Range 98.30 - 100.00
52wk Range 74.09 - 105.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Novartis a Good Stock to Buy Right Now?
The multinational pharma giant excels as an income play. 
Via The Motley Fool
Veterinary Healthcare Product Market to See Huge Growth : Pfizer, Merck, Johnson & Johnson
Stay up-to-date with Veterinary Healthcare Product Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire

Performance

YTD
+6.82%
+6.82%
1 Month
-6.11%
-6.11%
3 Month
+17.29%
+17.29%
6 Month
+8.55%
+8.55%
1 Year
+11.09%
+11.09%

More News

Read More
Looking At Novartis's Recent Unusual Options Activity
Via Benzinga
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Via MarketBeat
Topics Death
Exposures Death Product Safety
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
Via Benzinga
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
Via Investor's Business Daily
Is This Big Pharma Stock a Buy for Dividend Investors?
Via The Motley Fool
Smokeless Tobacco Treatment Market to See Booming Growth : Novartis, Pfizer, Johnson & Johnson, Cambrex
Via SBWire
Exposures Climate
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
Via FinancialNewsMedia
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
Via Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Via Benzinga
Why Is AVROBIO (AVRO) Stock Up 83% Today?
Via InvestorPlace
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Via MarketBeat
Topics Economy
Exposures Economy
Oral Cancer Treatment Market Projected to Show Strong Growth : Bristol-Myers Squibb, Qilu Pharmaceutical, Novartis
Via SBWire
AI for Pharma and Biotech Market Giants Spending Is Going to Boom : PFIZER, Abbott, SANOFI, Atomwise
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
What's Going On With Immix Biopharma Stock Today
Via Benzinga
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Via Benzinga
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
Via FinancialNewsMedia
Exposures COVID-19
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Via Investor's Business Daily
Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels
Via Benzinga
After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines
Via Benzinga
Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise
Via Investor's Business Daily
3 Top Biotech Stocks Defying the Bear Market
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.